The Fly

9 Meters Biopharma trial design increases odds of success, says Brookline

After 9 Meters Biopharma announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome, Brookline analyst Kumaraguru Raja said the trial design increases the odds of success given that hitting either of its endpoints can support an NDA filing. Raja reiterates a Buy rating and $74 price target on 9 Meters shares.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on NMTR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More